JSA
BMY icon

Jim Saulnier & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Jim Saulnier & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$369K Hold
6,076
– – 0.18% 93
2025
Q4 		$328K Hold
6,076
– – 0.17% 105
2025
Q3 		$274K Buy
+6,076
New +$284K 0.15% 112

Other funds holding BMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jim Saulnier & Associates's BMY Position: Q1 2026 in Review

Jim Saulnier & Associates held its Bristol-Myers Squibb (BMY) position steady in Q1 2026 at 6,076 shares worth $369K. The position accounts for 0.18% of the portfolio, ranked #93.

Jim Saulnier & Associates first reported a position in BMY in Q3 2025 and has held it in 3 quarters since. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Jim Saulnier & Associates held 6,076 shares of Bristol-Myers Squibb worth $369K as of Q1 2026.
  • Jim Saulnier & Associates left its Bristol-Myers Squibb share count unchanged in Q1 2026.
  • Bristol-Myers Squibb made up 0.18% of Jim Saulnier & Associates's portfolio in Q1 2026, its #93 holding.
  • Jim Saulnier & Associates first reported a position in Bristol-Myers Squibb in Q3 2025 and has held it in 3 quarters since.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Jim Saulnier & Associates's 13F filing for Q1 2026, filed 22 Apr 2026.